Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.
The safety analysis included 56 patients treated across three dose cohorts (2.5 mCi, 5.0 mCi, and 6.0 mCi).
During the trial, no dose-limiting toxicities (DLTs) were observed.
Additionally, there were no treatment-related discontinuations, and no Grade 5 adverse events occurred.
While grade ≥3 treatment-related adverse events were reported in 21 patients (37.5%), with only one instance of transient Grade 4 lymphopenia that resolved, efficacy was evaluated in 25 patients (2 from Cohort 1 and 23 from Cohort 2).
In Cohort 2, 9 of 23 patients (39%) achieved an objective response, with 8 previously confirmed.
Overall, 19 of 25 patients (76%) remained progression-free and alive at the time of the update.
The company also confirmed that DLT assessment for Cohort 3 has been completed, with no DLTs identified, clearing the way for additional patient enrollment at the 6.0 mCi dose level.